BOSTON--(BUSINESS WIRE)--Feb. 8, 2006--Point Therapeutics, Inc. (NASDAQ: POTP) announced today that it enrolled the first patient in the company’s second Phase 3 clinical trial, which will evaluate talabostat in combination with pemetrexed versus pemetrexed with placebo in patients with metastatic non-small cell lung cancer (NSCLC).
